healthcare News

Alnylam, Roche Advance Hypertension Drug to Pivotal Phase 3 Trial
Healthcare
5mo ago

Alnylam, Roche Advance Hypertension Drug to Pivotal Phase 3 Trial

Zilebesiran, a twice-yearly injection, will be tested in 11,000 high-risk patients following promising mid-stage results.

Amarin Surges on Positive VASCEPA Trial Data
Healthcare
5mo ago

Amarin Surges on Positive VASCEPA Trial Data

New analyses from the REDUCE-IT trial show a 9% reduction in hospitalizations, bolstering the drug's profile amid ongoing generic competition.

BridgeBio Drug Acoramidis Shows 44% Cut in Heart-Related Deaths
Healthcare
5mo ago

BridgeBio Drug Acoramidis Shows 44% Cut in Heart-Related Deaths

Long-term study data presented at a major cardiology conference reinforces the drug's potential in treating a rare heart condition.

MSP Recovery Secures $55M Lifeline at a Heavy Cost to Shareholders
Healthcare
5mo ago

MSP Recovery Secures $55M Lifeline at a Heavy Cost to Shareholders

Financing deal carries risk of 46% equity dilution, coupled with a 1-for-7 reverse stock split to maintain Nasdaq listing.

Cytokinetics Drug Bests Standard Care in Heart Study
Healthcare
5mo ago

Cytokinetics Drug Bests Standard Care in Heart Study

Aficamten proves superior to metoprolol for hypertrophic cardiomyopathy, positioning the drug for a potential shift in treatment standards.

InflaRx Stock Surges on EU Approval for Sepsis Drug
Healthcare
5mo ago

InflaRx Stock Surges on EU Approval for Sepsis Drug

Shares soared over 36% after the European Commission authorized GOHIBIC for treating critically ill COVID-19 patients.

Sanofi Wins FDA Approval for New Blood Disorder Drug Wayrilz
Healthcare
5mo ago

Sanofi Wins FDA Approval for New Blood Disorder Drug Wayrilz

First-in-class BTK inhibitor for immune thrombocytopenia (ITP) projected to achieve multi-billion dollar peak sales.

Biogen, Eisai Win FDA Nod for At-Home Alzheimer's Drug Leqembi Iqlik
Healthcare
5mo ago

Biogen, Eisai Win FDA Nod for At-Home Alzheimer's Drug Leqembi Iqlik

The new subcutaneous autoinjector offers a more convenient weekly maintenance option for patients after initial IV treatment.